ArticlePloS one2013
miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- The dual roles of exosomes in prostate cancer: mechanisms in tumorigenesis and avenues for clinical translation.Frontiers in immunology · 2026Review
- Regulation of gene expression by modulating microRNAs through Epigallocatechin-3-gallate in cancer.Molecular biology reports · 2024Review
- The multifaceted role of extracellular vesicles in prostate cancer-a review.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors.PLoS computational biology · 2022Article
- The miRNome of canine invasive urothelial carcinoma.Frontiers in veterinary science · 2022Article
- Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.Journal of clinical laboratory analysis · 2021Article
- Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.Oncology reports · 2021Observational
- Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.Cancer cell international · 2021Article
- Role of Exosomes in Prostate Cancer Metastasis.International journal of molecular sciences · 2021Review
- lncRNA MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance.Cancer management and research · 2021Article
- miR-105 Promotes the Progression and Predicts the Prognosis for Oral Squamous Cell Carcinoma (OSCC).Cancer management and research · 2020Article
- Exploring the Potential of MicroRNA Let-7c as a Therapeutic for Prostate Cancer.Molecular therapy. Nucleic acids · 2019Review
- A natural WNT signaling variant potently synergizes with Cdkn2ab loss in skin carcinogenesis.Nature communications · 2019Article
- The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer.Frontiers in oncology · 2019Review
- circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6.OncoTargets and therapy · 2019Article
- Long Intergenic Noncoding RNA 00261 Acts as a Tumor Suppressor in Non-Small Cell Lung Cancer via Regulating miR-105/FHL1 Axis.Journal of Cancer · 2019Article
- Joint testing and false discovery rate control in high-dimensional multivariate regression.Biometrika · 2018Article
- Reduced miR-105-1 levels are associated with poor survival of patients with non-small cell lung cancer.Oncology letters · 2017Article
- High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1.Oncotarget · 2017Article
- MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
A significant role for micro (mi)RNA in the regulation of gene expression in tumours has been recently established. In order to further understand how miRNA expression may contribute to prostate tumour growth and progression, we evaluated expression of miRNA in two invasive prostate tumour lines, PC3 and DU145, and compared it to that in normal prostate epithelial cells. Although a number of miRNAs were differentially expressed, we focused our analysis on miR-105, a novel miRNA not previously linked to prostate cancer. miR-105 levels were significantly decreased in both tumour cell lines in comparison to normal prostate epithelial cells. To determine its potential role in prostate cancer pathogenesis, we overexpressed miR-105 in both PC3 and DU145 cells and determined its effect on various tumourigenic properties. miR-105 overexpression inhibited tumour cell proliferation, tumour growth in anchorage-independent three-dimensional conditions and tumour invasion in vitro, properties of highly aggressive tumour cells. Of potential clinical significance, miR-105 overexpression inhibited tumour growth in vivo in xenograft models using these cell lines. We further identified CDK6 as a putative target of miR-105 which is likely a main contributor to the inhibition of tumour cell growth observed in our assays. Our results suggest that miR-105 inhibits tumour cell proliferation and hence may represent a novel therapeutically relevant cellular target to inhibit tumour growth or a marker of aggressive tumours in prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.